NPI: 1083959464 · CHULA VISTA, CA 91911 · Federally Qualified Health Center (FQHC) · NPI assigned 12/11/2012
Authorized official ROMAN, RICARDO controls 20+ related entities in our dataset. Read more
| Authorized Official | ROMAN, RICARDO (CHIEF FINANCIAL OFFICER) |
| Parent Organization | FAMILY HEALTH CENTERS OF SAN DIEGO |
| NPI Enumeration Date | 12/11/2012 |
Other providers sharing the same authorized official: ROMAN, RICARDO
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 8,172 | $800K |
| 2019 | 13,442 | $727K |
| 2020 | 8,142 | $445K |
| 2021 | 1,571 | $115K |
| 2022 | 7,640 | $513K |
| 2023 | 14,101 | $911K |
| 2024 | 4,239 | $279K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| T1015 | Clinic visit/encounter, all-inclusive | 28,510 | 23,955 | $3.78M |
| 90834 | Psychotherapy, 45 minutes with patient | 432 | 370 | $7K |
| 90791 | Psychiatric diagnostic evaluation | 12 | 12 | $2K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6,316 | 5,837 | $1K |
| 93000 | 28 | 28 | $599.20 | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5,071 | 4,714 | $429.36 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 306 | 306 | $405.20 |
| 84443 | Thyroid stimulating hormone (TSH) | 817 | 816 | $369.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1,416 | 1,406 | $368.92 |
| 80061 | Lipid panel | 949 | 947 | $346.20 |
| 80053 | Comprehensive metabolic panel | 1,120 | 1,109 | $330.84 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 959 | 954 | $310.50 |
| 83036 | Hemoglobin; glycosylated (A1C) | 926 | 926 | $222.04 |
| 98960 | 20 | 16 | $215.20 | |
| 82951 | 16 | 16 | $203.29 | |
| 81002 | 75 | 68 | $161.25 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1,743 | 1,599 | $126.70 |
| 86592 | 221 | 221 | $86.52 | |
| 81025 | 92 | 92 | $84.66 | |
| 96127 | 443 | 438 | $75.36 | |
| 87210 | 54 | 54 | $65.42 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 182 | 182 | $31.17 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 182 | 182 | $31.07 |
| 36415 | Collection of venous blood by venipuncture | 1,035 | 998 | $13.50 |
| 86803 | 88 | 88 | $12.57 | |
| 85018 | 152 | 152 | $4.14 | |
| 97803 | 1,382 | 1,377 | $0.00 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 310 | 306 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 158 | 156 | $0.00 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 228 | 225 | $0.00 |
| 99173 | 697 | 696 | $0.00 | |
| 90756 | 326 | 326 | $0.00 | |
| 90461 | 26 | 26 | $0.00 | |
| 83540 | 25 | 25 | $0.00 | |
| 82947 | 21 | 21 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 86 | 85 | $0.00 |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 12 | 12 | $0.00 |
| 96160 | 24 | 24 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 31 | 31 | $0.00 |
| 86480 | 26 | 26 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 81 | 80 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 25 | 25 | $0.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 134 | 134 | $0.00 |
| 81003 | 89 | 86 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 114 | 114 | $0.00 |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 67 | 67 | $0.00 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 37 | 37 | $0.00 |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 12 | 12 | $0.00 |
| 82274 | 17 | 17 | $0.00 | |
| 99404 | 18 | 18 | $0.00 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 15 | 12 | $0.00 |
| 99401 | 17 | 17 | $0.00 | |
| 87340 | 46 | 46 | $0.00 | |
| 92551 | 481 | 479 | $0.00 | |
| 97802 | 200 | 200 | $0.00 | |
| 90686 | 187 | 187 | $0.00 | |
| 86704 | 110 | 110 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 109 | 107 | $0.00 |
| 94760 | 54 | 50 | $0.00 | |
| 86706 | 131 | 131 | $0.00 | |
| 99000 | 221 | 219 | $0.00 | |
| 82728 | 12 | 12 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 20 | 20 | $0.00 |
| 99406 | 31 | 28 | $0.00 | |
| 81015 | 57 | 57 | $0.00 | |
| 90674 | 154 | 154 | $0.00 | |
| 87428 | 13 | 13 | $0.00 | |
| 81001 | 100 | 99 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 38 | 38 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 14 | 14 | $0.00 |
| 87070 | 110 | 108 | $0.00 | |
| 83550 | 12 | 12 | $0.00 | |
| 99459 | 12 | 12 | $0.00 | |
| 90677 | 19 | 19 | $0.00 | |
| H0001 | Alcohol and/or drug assessment | 33 | 22 | $0.00 |